Nucryst Doubles On FDA Approval For Prescription Cream

Nucryst Pharmaceuticals Corp. (NCST) shares shot through the roof and then some Friday morning, rising more than 100%, following the company announcement late Thursday afternoon that the U.S. Food & Drug Administration has approved a prescription-only topical antimicrobial cream.

Nucryst, whose patented nanocrystalline silver compound is currently used in Smith & Nephew plc's (NYSE:SNN) Acticoat advanced wound care products, will now begin marketing the new cream that will be used to fight against infections and inflammation.

Nucryst president and CEO Scott Gillis said in a statement that market plans and timing for this product will be determined as part of the commercialization process.

NCST 1-yr chart:
ncst chart